

Evidence-Based Assessment of a Closed Blood Sampling System

Contents

Reflects an evidence-based assessment of the value of the VAMP system in context of:

- 1 Blood sampling burden
- 2 Closed blood sampling systems
- 3 Blood loss and hemoglobin decline
- 4 Transfusions
- 5 Hospital resource use and costs
- 6 Contamination and infection
- 7 Best practices for blood conservation
- 8 Alignment to healthcare reform
- 9 VAMP system clinical evidence-base
- 10 Partnering with Edwards

Meeting the challenges of the new healthcare landscape

In a changing healthcare landscape, hospitals need to achieve new quality standards for patient care while balancing an increasing cost burden. Evidence-based decision-making, and measures such as value-based purchasing (VBP), have become essential in hospital healthcare reform, allowing for increased positive outcomes with the provision of cost-effective care.

Blood sampling is a routine and vital procedure conducted frequently in the hospital setting; however, it can be associated with a large amount of blood loss^[1-7], unnecessary blood waste^[3, 6, 8-12], and risk of contamination^[13-16]. This can have important clinical consequences such as anemia^[5, 17-22], transfusions^[19, 23, 24], and infections which can result in poor patient outcomes^[1, 22, 25], as well as increased hospital costs^[26, 27].

The VAMP (Venous Arterial blood Management Protection) system is an evidence-based solution that combines the safety and simplicity of needleless blood sampling with a unique reservoir designed to conserve blood by allowing the clinician to re-infuse excess blood not needed for the sample. Several clinical studies have demonstrated improved patient outcomes with the VAMP system compared with conventional sampling methods^[28-31]. In addition, economic analyses predict cost avoidance with the VAMP system such that acquisition cost can be completely offset^[28,29, 30]. The VAMP system is thus aligned with health reform measures and can help hospitals optimize patient care and cost efficiencies.



Edwards

Blood Sampling Burden

Blood sampling is a common hospital procedure that results in notable blood loss, particularly in critically ill patients.

Blood Discarding: For the purpose of clearing catheter lines, a portion of blood is typically discarded as waste during blood sampling

- Blood samples may be drawn from 5 to 24 times a day in the intensive care unit (ICU)^[1, 2] with daily blood draw volume between 26 to 478 mL depending on comorbidity.^[2-7]
- Patients with catheters are subject to more blood sampling and blood loss vs. patients without catheters.^[33]
- Discarding of blood is frequently conducted with traditional blood sampling^[8, 9] and can substantially contribute to blood loss:
 - A European study found that 88% of ICU patients had blood discarded.^[8]
 - The amount of blood discarded with each blood draw often varies from 2 to 10 mL.^[3, 10-12]
 - This discarded blood can account for 24% to 30% of total daily blood loss in critically ill patients.^[6]

Blood loss due to sampling with discarding can lead to a decline in hemoglobin (Hb), which can contribute to anemia.

Discarding blood after blood sampling is a predictor of Hb decline and anemia.^[21,22]

- Blood sampling is highly associated with decreases in Hb (*Table 1*) and hematocrit and can contribute to anemia.^[17]
- Several studies cite anemia as a result of blood loss from blood sampling with the risk of moderate to severe anemia increasing by 18% for every 50 mL of blood drawn.^[5, 17-20]
- Anemia is associated with substantial burden and increased risk of organ injury and mortality.^[1, 2, 34, 35]

TABLE 1: Volume of Blood Draw and Predicted Drops in Hb

| Volume of Blood Draw | Expected Change in Hb (g/L); 95% CI |
|----------------------|-------------------------------------|
| 10 mL | • 0.7 (0.5 to 0.9) |
| 50 mL | • 3.5 (2.4 to 4.6) |
| 100 mL | • 8.0 (4.8 to 10.2) |
| 200 mL | • 14.0 (9.6 to 18.4) |

Improving Patient Outcomes

Closed blood sampling systems allow for blood re-infusion, providing an important alternative to conventional sampling methods.



FIGURE 1: VAMP Adult System

- Closed blood sampling systems, used with catheters, have reservoirs that hold blood and flush solution to allow sample collection without dilution and blood re-infusion rather than discard.^[15]
- The VAMP system is a needleless device designed to reduce infection risk and promote blood conservation while providing consistent sampling for safety and reliability with unique features:



VAMP Reservoir:
Allows clinicians to re-infuse “clearing volume” blood



Blunt Cannula: Used to draw samples from VAMP system, no needle required



Z-site sample port:
Reduces residual blood build-up, allowing for *undiluted samples*

Blood loss and Hb level decline are reduced with the VAMP closed blood sampling system vs. conventional sampling.




FIGURE 2: Comparison of VAMP system vs. conventional blood sampling for A) Blood drawn and discarded and B) Decrease in Hb levels from admission to discharge

Improving Patient Outcomes

The VAMP system has demonstrated reduced transfusion needs vs. conventional sampling. A lower transfusion risk may lead to less transfusion complications.

Use of the VAMP system significantly reduces transfusion risk compared to conventional blood sampling method. [28,31]

- Several studies demonstrate that greater blood loss from sampling is associated with higher transfusion risk in ICU patients. [19, 23, 24]
- A meta-analysis [32] of randomized controlled trials (RCTs) shows a significant reduction in transfusion risk with the VAMP system vs. conventional methods [28-30] (Figure 3).




FIGURE 3: A) RCTs comparing transfusion risk between VAMP system and conventional blood sampling methods; B) Meta-analysis of the three RCTs showing significant reduction in risk of transfusion with VAMP system vs. conventional sampling (p=0.004). [28-30] **Caveat:** Meta-analysis results for transfusion risk should be interpreted in context of institution-specific patient populations and transfusion protocols.

Blood transfusions are linked to many adverse outcomes:

- Transfusions may cause: hepatitis, infections, sepsis, transfusion-related acute lung injury, and many more complications. [1]
- In a U.S. study, the risk of infection increased by 29% per unit of red blood cell (RBC) transfusion. [37]
- Critically ill patients in the ICU are likely to be more at risk of the immunosuppressive and microcirculatory complications of blood transfusions than the general population. [22]
- The U.S. CRIT study found 44% of patients in ICU received one or more RBC units with 4% being associated with a transfusion-related complication. [25] The study also reported a mortality ratio of 1.65 (95%CI: 1.35 to 2.03) with RBC transfusions. [25]

Blood transfusions are associated with various types of complications and increased mortality risk. [1]

Reducing Hospital Costs

The VAMP closed blood sampling system may lead to hospital-related cost avoidance compared with conventional sampling in hospitals.

The VAMP system may help avoid hospital costs by reducing transfusion incidence with one transfusion averted in every 6 to 8 patients that use the VAMP system. [28, 29, 30]

- Avoiding blood transfusions is associated with high cost-savings for hospitals given that transfusions are one of the largest cost centers in every hospital. [26, 27]
- The incremental cost of the VAMP system (Edwards, 2013) is only a fraction of the direct cost of a RBC transfusion which varies up to \$210 (US) [32, 38, 39] and €439 (EU) per RBC unit. [40]

A U.S. economic analysis, informed by clinical studies, shows that the VAMP system is associated with cost-savings for hospitals [32]:

- For a hospital with 500 ICU patients annually, the VAMP system was associated with a cost avoidance of \$29,270 per year (Figure 4A). [32]
- Results were robust to changes in assumptions as the VAMP system showed cost avoidance in many scenarios (Figure 4B). [32]




FIGURE 4: A) Comparison of annual transfusion and supply-related costs between VAMP system and conventional sampling. [32] B) Tornado diagram of sensitivity analysis results for VAMP system vs. conventional blood sampling methods. [32]

Reducing Hospital Infection

The risk of contamination is reduced with the VAMP closed blood sampling system versus conventional methods, thereby potentially leading to fewer hospital-acquired infections and associated costs.

Annually, 50,000 U.S. patients have a catheter-related bloodstream infection (CRBSI) with an average per case cost of \$4,888 USD.^[46,47]

Contamination rates have been found to be significantly lower with the VAMP system compared to conventional blood sampling.^[16]

There is a high contamination risk of the equipment used in conventional blood sampling with catheters:

- Stopcocks used as blood sampling ports can easily become contaminated with bacteria.^[13,14]
- Intra-operative 3-way stopcock contamination has been found to range between 3.2 to 61%.^[14, 41-44]
- Transmission of bacteria, including vancomycin-resistant enterococci (VRE), to intravenous stopcock sets occurred in 32% of cases (95%CI: 20.6% to 44.9%) during the practice of general anaesthetists.^[45]

Contamination risk can be reduced with closed versus open blood sampling methods by eliminating access through open blood sampling ports and the need for stopcocks.^[16, 48]

- An RCT shows the VAMP system is associated with significantly less contamination vs. conventional sampling (*Figure 5*).

A lower contamination risk, with the VAMP system vs. conventional sampling, may present potential for reduction in catheter-related bloodstream infection (CRBSI).




FIGURE 5: Study results comparing contamination rates using the VAMP system versus conventional blood sampling methods^[15,16]

Improving Guideline Compliance

The VAMP closed blood sampling system may facilitate standardization to best practices for blood conservation.

TABLE 2: Several organizations recommend strategies to avoid blood waste through blood sampling devices

Blood Sampling Guidelines

| | |
|--|---|
| Agency for Healthcare Research & Quality, 2009 ^[49] | <ul style="list-style-type: none">• Use of blood conservation devices for reinfusion of waste blood with sampling is associated with reduction in phlebotomy volume |
| British Committee for Standards in Haematology, 2013 ^[50] | <ul style="list-style-type: none">• Blood conservation sampling devices should be considered to reduce phlebotomy-related blood loss |
| US Society for the Advancement of Blood Management (Clinical Standards), 2013 ^[51] | <ul style="list-style-type: none">• Reducing or eliminating blood discard should be done and reinfusion of discard should be performed when practical |

The VAMP system is needleless, thereby avoiding needle sticks in healthcare workers.

There is a high burden associated with needle stick injury:

- In the USA, hospital fines associated with needle stick injuries reported to range from \$7,000 to \$70,000 for failure to comply to the Needlestick Safety and Prevention Act.^[52]
- Needle sticks have been blamed for causing 40% of hepatitis B infections, 40% of hepatitis C infections, and 2.5% of HIV infections among healthcare workers.^[53]
- Clinical practice guidelines promote the use of needleless medical devices and systems to minimize risk of needle stick injury.^[54-56]
- An estimated 83% of needle stick injuries could be avoided with the use of needle devices with safety features or by using needleless systems.^[57]
- The blunt cannula attached to the VAMP system sampling syringe prevents the chance for needle injury when drawing blood (i.e. no needle). This is in contrast to some blood sampling methods where transferring of blood to a vial through a needle is required.

According to the CDC, 385,000 sharp-related injuries occur annually in the US while 1 million needle stick injuries are estimated annually in the EU. ^[58-60]

Aligning with Healthcare Reform Measures

The VAMP system demonstrates improved outcomes aligned with achieving U.S. healthcare reform objectives and hospital quality performance measures.

Hospitals require evidence-based decision-making to ensure better, affordable, cost-effective care to optimize population health.^[61-65]

Changing Healthcare Landscape

Primary Objectives of the Triple Aim in Patient Protection and Affordable Care Act^[61,62]

- 1) Improve quality of patient care
- 2) Improve population health
- 3) Affordable care

Hospital Goals with Healthcare Reform^[63]

- Improve quality of care and patient satisfaction
- Improve patient outcomes
- Increase total performance score (TPS)
- Reduce hospital-acquired conditions (e.g., infection)
- Decrease episode of care costs


Several healthcare reform measures are applicable to hospital setting, such as^[64,65]

- *Value Based Purchasing (VBP)*: Encourages quality of care in hospitals; measured by TPS
- *Bundled Payments*: Payment for episode of care rather than fee for service (FFS)

Impact on Hospitals

With healthcare reform, hospitals will face financial accountability^[63]

- Earn dollars or lose dollars based on quality improvements vs. benchmarks
- Restrictions in reimbursement related to hospital-acquired conditions



The VAMP System as an Evidence-Based Hospital Product

Hospital product adoption goals

Hospitals should choose products that are evidence-based and cost-effective to help support the changing healthcare landscape and achieve better and affordable care

The VAMP system is an evidence-based solution aligned with needs of new hospital landscape

- Improves patient outcomes (e.g., fewer blood transfusions)^[28,31,32]
- Reduces contamination and potential for infections^[15,16]
- Predicted cost avoidance due to less transfusions^[28, 29, 30]
- Proven through numerous randomized studies (*Table 3*)

Evidence-Based Solution

The VAMP system is the only blood sampling system with published data proven to significantly reduce transfusion needs and contamination rates compared to conventional sampling. ^[16,22,28,31]

TABLE 3: Published Studies of Closed Blood Sampling Systems in Critical Care

| Study | Study Design | Comparators | Sample Size | Main Outcomes |
|-----------------------------------|--------------------------|--------------------------|-------------|---|
| Silver 1993 ^[66] | RCT (USA) | SafeDraw Conventional | 31 | Blood discarded over 7 day study period |
| Silver 1993 ^[67] | RCT (USA) | SafeDraw Conventional | 20 | Partial thromboplastin time |
| Peruzzi 1993 ^[21] | RCT (USA) | VAMP Conventional | 100 | Blood loss, hemoglobin concentrations, and blood transfusions |
| Peruzzi 1996 ^[48] | RCT (USA) | VAMP SafeDraw | 40 | Microbial contamination and infection |
| Woda 1999 ^[68] | RCT (USA) | SafeSet Conventional | 99 | Damping coefficient and resonant frequencies, discard volume, and blood sample size |
| Thorpe 2000 ^[15] | RCT (UK) | VAMP Conventional | 100 | Blood transfusions, hemoglobin levels, and microbial contamination |
| Morón 2003 ^[30] | RCT (Spain) | VAMP Conventional | 58 | Transfusion risk and hemoglobin concentrations |
| Maclsaac 2003 ^[28] | RCT (Australia) | VAMP Conventional | 160 | Hemoglobin concentration, blood loss, and transfusion risk |
| Mahdy 2009 ^[36] | RCT (UK) | VAMP Conventional | 39 | Diagnostic blood loss and hemoglobin concentration |
| Rezende 2010 ^[29] | RCT (Brazil) | VAMP Conventional | 127 | Blood loss, hemoglobin concentration, and transfusions |
| Mukhopadhyay 2010 ^[31] | Before-After (Singapore) | VAMP Conventional | 250 | Transfusion requirements, hemoglobin concentration, and blood loss |
| Oto 2012 ^[16] | RCT (Japan) | VAMP Conventional | 216 | Microbial contamination and infection |

The VAMP system has been evaluated in numerous clinical studies across the world (*Table 3*).

The Edwards Lifesciences Advantage

Partnering with Edwards for your blood management and hemodynamic monitoring needs provides important advantages to your hospital setting.

Edwards offers a comprehensive product range for closed blood sampling across patient populations:



VAMP Adult System



VAMP Plus System




VAMP Jr. System

Edwards is committed to hemodynamic excellence in caring for the acutely ill:

- The Edwards portfolio consists of hemodynamic management solutions for monitoring patients of varying clinical complexity. Each employs advanced technologies to provide optimum insight and maximum clinical efficiency.
- Several products are compatible and may smoothly integrate with the VAMP system, (e.g. TruWave disposable pressure transducer with various types of multi-channel pressure cables enabling connection to wide variety of bedside monitors).

For over 40 years, Edwards has partnered with clinicians to develop products and systems that advance the treatment of the acutely ill



Edwards is focused on helping clinicians enhance knowledge and standardize practice to improve the quality and efficiency of care. Edwards is dedicated to providing:

- Evidence-based programs such as Sepsis Management and Enhanced Surgical Recovery Programs that facilitate implementation and compliance of protocolized care in the OR and ICU
- Expansive educational tools, resources and clinical support

Edwards is committed to providing your institution, clinicians and staff with the highest levels of customer service and support, including:

- Best-In-Class, 24/7 Technical Support – Simply call **800-822-9837** anytime, day or night
- Live Customer Service – Call **800-424-3278** to speak to a customer service representative
- Integrated Delivery Network – Our network of manufacturing and warehouse facilities are strategically located to provide product delivery within 24 hours of placing an order, if needed
- Educational Tools and Support – Edwards offers a full range of on-line, in-print and on-site programs that are available to your clinicians or staff, visit **www.Edwards.com/CEducation**

REFERENCES

1. Tinmouth, A.T., L.A. McIntyre, and R.A. Fowler, *Blood conservation strategies to reduce the need for red blood cell transfusion in critically ill patients*. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2008. **178**(1): p. 49-57.
2. Vincent, J.L., et al., *Anemia and blood transfusion in critically ill patients*. JAMA, 2002. **288**(12): p. 1499-507.
3. Barth, M.D., et al., *Blood Conservation: What Is Current Blood Draw Practice?* Journal of infusion nursing : the official publication of the Infusion Nurses Society, 2013. **36**(5): p. 323-328.
4. Smoller, B.R., M.S. Kruskall, and G.L. Horowitz, *Reducing adult phlebotomy blood loss with the use of pediatric-sized blood collection tubes*. Am J Clin Pathol, 1989. **91**(6): p. 701-3.
5. Eyster, E. and J. Bernene, *Nosocomial anemia*. JAMA, 1973. **223**(1): p. 73-4.
6. Henry, M.L., W.L. Garner, and P.J. Fabri, *Iatrogenic anemia*. Am J Surg, 1986. **151**(3): p. 362-3.
7. Andrews, T., H. Waterman, and V. Hillier, *Blood gas analysis: a study of blood loss in intensive care*. Journal of advanced nursing, 1999. **30**(4): p. 851-7.
8. O'Hare, D. and R.J. Chilvers, *Arterial blood sampling practices in intensive care units in England and Wales*. Anaesthesia, 2001. **56**(6): p. 568-71.
9. Low, L.L., G.R. Harrington, and D.P. Stoltzfus, *The effect of arterial lines on blood-drawing practices and costs in intensive care units*. Chest, 1995. **108**(1): p. 216-9.
10. Yucha, C.B. and E. DeAngelo, *The minimum discard volume: accurate analysis of peripheral hematocrit*. J Intraven Nurs, 1996. **19**(3): p. 141-6.
11. Keller, C.A., *Methods of drawing blood samples through central venous catheters in pediatric patients undergoing bone marrow transplant: results of a national survey*. Oncol Nurs Forum, 1994. **21**(5): p. 879-84.
12. Holmes, K.R., *Comparison of push-pull versus discard method from central venous catheters for blood testing*. J Intraven Nurs, 1998. **21**(5): p. 282-5.
13. Walrath, J.M., et al., *Stopcock: bacterial contamination in invasive monitoring systems*. Heart Lung, 1979. **8**(1): p. 100-4.
14. Shinozaki, T., et al., *Bacterial contamination of arterial lines. A prospective study*. JAMA, 1983. **249**(2): p. 223-5.
15. Thorpe, S. and A.N. Thomas, *The use of a blood conservation pressure transducer system in critically ill patients*. Anaesthesia, 2000. **55**(1): p. 27-31.
16. Oto, J., et al., *Comparison of bacterial contamination of blood conservation system and stopcock system arterial sampling lines used in critically ill patients*. American journal of infection control, 2012. **40**(6): p. 530-4.
17. Thavendiranathan, P., et al., *Do blood tests cause anemia in hospitalized patients? The effect of diagnostic phlebotomy on hemoglobin and hematocrit levels*. Journal of general internal medicine, 2005. **20**(6): p. 520-4.
18. Salisbury, A.C., et al., *Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction*. Archives of internal medicine, 2011. **171**(18): p. 1646-53.
19. Chant, C., G. Wilson, and J.O. Friedrich, *Anemia, transfusion, and phlebotomy practices in critically ill patients with prolonged ICU length of stay: a cohort study*. Critical care, 2006. **10**(5): p. R140.
20. Lin, J.C., et al., *Phlebotomy overdraw in the neonatal intensive care nursery*. Pediatrics, 2000. **106**(2): p. E19.
21. Peruzzi, W.T., et al., *A clinical evaluation of a blood conservation device in medical intensive care unit patients*. Critical care medicine, 1993. **21**(4): p. 501-6.
22. Page, C., A. Retter, and D. Wyncoll, *Blood conservation devices in critical care: a narrative review*. Annals of intensive care, 2013. **3**(1): p. 14.

23. Corwin, H.L., K.C. Parsonnet, and A. Gettinger, *RBC transfusion in the ICU. Is there a reason?* Chest, 1995. **108**(3): p. 767-71.
24. Bateman, S.T., et al., *Anemia, blood loss, and blood transfusions in North American children in the intensive care unit.* Am J Respir Crit Care Med, 2008. **178**(1): p. 26-33.
25. Corwin, H.L., et al., *The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States.* Critical care medicine, 2004. **32**(1): p. 39-52.
26. Masimo. *Better Care Program Enables Select Hospitals to Adopt SpHb Hospital-Wide to Improve Patient Outcomes with Guaranteed Savings.* Feb. 14th 2014]; Available from: <http://ir.masimo.com/phoenix.zhtml?c=117065&p=irol-newsArticle&id=1661005>.
27. Premier Healthcare Alliance, *Best Practices in Blood Utilization.* Premier healthcare alliance Fall 2012 Economic Outlook, 2012.
28. MacIsaac, C.M., et al., *The influence of a blood conserving device on anaemia in intensive care patients.* Anaesth Intensive Care, 2003. **31**(6): p. 653-7.
29. Rezende E, F.M., Manoel Da Silva Junior J, et al, *Closed system for blood sampling and transfusion in critically ill patients.* Rev Bras Ter Intensiva, 2010. **22**: p. 5-10.
30. Moron N., J.E., Moreno I., Lazaro A., *Dispositivo VAMP Beneficis para el paciente critico.* Rev ROL Enf, 2003. **26**(9): p. 591-594.
31. Mukhopadhyay, A., et al., *The use of a blood conservation device to reduce red blood cell transfusion requirements: a before and after study.* Critical care, 2010. **14**(1): p. R7.
32. Edwards Lifesciences Data on File, 2013.
33. Fowler, R.A. and M. Berenson, *Blood conservation in the intensive care unit.* Critical care medicine, 2003. **31**(12 Suppl): p. S715-20.
34. Hare, G.M., J. Freedman, and C. David Mazer, *Review article: risks of anemia and related management strategies: can perioperative blood management improve patient safety?* Can J Anaesth, 2013. **60**(2): p. 168-75.
35. Rudis, M.I., et al., *Managing anemia in the critically ill patient.* Pharmacotherapy, 2004. **24**(2): p. 229-47.
36. Mahdy, S., et al., *Evaluation of a blood conservation strategy in the intensive care unit: a prospective, randomised study.* Middle East J Anesthesiol, 2009. **20**(2): p. 219-23.
37. Horvath, K.A., et al., *Blood transfusion and infection after cardiac surgery.* Ann Thorac Surg, 2013. **95**(6): p. 2194-201.
38. Toner, R.W., et al., *Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services.* Appl Health Econ Health Policy, 2011. **9**(1): p. 29-37.
39. Shander, A., et al., *Activity-based costs of blood transfusions in surgical patients at four hospitals.* Transfusion, 2010. **50**(4): p. 753-65.
40. Abraham, I. and D. Sun, *The cost of blood transfusion in Western Europe as estimated from six studies.* Transfusion, 2012. **52**(9): p. 1983-8.
41. Loftus, R.W., et al., *Prevention of intravenous bacterial injection from health care provider hands: the importance of catheter design and handling.* Anesth Analg, 2012. **115**(5): p. 1109-19.
42. Loftus, R.W., et al., *Multiple reservoirs contribute to intraoperative bacterial transmission.* Anesth Analg, 2012. **114**(6): p. 1236-48.
43. Loftus, R.W., et al., *Hand contamination of anesthesia providers is an important risk factor for intraoperative bacterial transmission.* Anesth Analg, 2011. **112**(1): p. 98-105.
44. Crow, S., et al., *Microbial contamination of arterial infusions used for hemodynamic monitoring: a randomized trial of contamination with sampling through conventional stopcocks versus a novel closed system.* Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America, 1989. **10**(12): p. 557-61.

45. Loftus, R.W., et al., *Transmission of pathogenic bacterial organisms in the anesthesia work area*. *Anesthesiology*, 2008. **109**(3): p. 399-407.
46. De Gaudio, A.R. and A. Di Filippo, *Device-related infections in critically ill patients. Part I: Prevention of catheter-related bloodstream infections*. *J Chemother*, 2003. **15**(5): p. 419-27.
47. Ramritu, P., et al., *Catheter-related bloodstream infections in intensive care units: a systematic review with meta-analysis*. *Journal of advanced nursing*, 2008. **62**(1): p. 3-21.
48. Peruzzi, W.T., et al., *Microbial contamination of blood conservation devices during routine use in the critical care setting: results of a prospective, randomized trial*. *Critical care medicine*, 1996. **24**(7): p. 1157-62.
49. Napolitano, L.M., *Scope of the problem: epidemiology of anemia and use of blood transfusions in critical care*. *Critical care*, 2004. **8 Suppl 2**: p. S1-8.
50. Retter, A., et al., *Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients*. *Br J Haematol*, 2013. **160**(4): p. 445-64.
51. SABM. *Administrative and Clinical Standards for Patient Blood Management Programs, 2nd Edition*. 2013 Oct. 16, 2013]; Available from: <http://www.sabm.org/sites/sabm.org/files/Second-Edition-Draft-of-Administrative-and-Clinical-Standards-For-Patient-Blood-Management-Programs.pdf>.
52. Marini, M.A., M. Giangregorio, and J.C. Kraskinski, *Complying with the Occupational Safety and Health Administration's Bloodborne Pathogens Standard: implementing needleless systems and intravenous safety devices*. *Pediatr Emerg Care*, 2004. **20**(3): p. 209-14.
53. Nurses, I.C.o., *ICN, WHO lead effort to reduce needlesticks*. *Int Nurs Rev*, 2004. **51**(1): p. 11-2.
54. Wilburn S, E.G., *A WHO-ICN Collaboration: Preventing Needlestick Injuries among Healthcare Workers*. *INT J OCCUP ENVIRON HEALTH*, 2004. **10**: p. 451-456.
55. Department of Labor, O.S.a.H.A., *Occupational Exposure to Bloodborne Pathogens: Needlesticks and Other Sharps Injuries*. *Federal Register*, 2001. **66**(12): p. 5318-5325.
56. Joint Commission on Accreditation of Healthcare Organizations (JCAHO). *Sentinel Event Alert: Preventing needlestick and sharp injuries*. Sept 2001 Sept. 28, 2013]; Available from: http://www.jointcommission.org/assets/1/18/SEA_22.pdf.
57. Tan, L., J.C. Hawk, 3rd, and M.L. Sterling, *Report of the Council on Scientific Affairs: preventing needlestick injuries in health care settings*. *Archives of internal medicine*, 2001. **161**(7): p. 929-36.
58. Centers for Disease Control and Prevention. *The Stop Sticks Campaign: Campaign User's Guide and Resources*. Updated 2013 Sept 29, 2013]; Available from: <http://www.cdc.gov/niosh/stopsticks/>.
59. Macklin, D. and P.L. Blackburn, *Intravenous needle-free injection devices: new information for compounding pharmacists*. *Int J Pharm Compd*, 2013. **17**(2): p. 100-10.
60. Eucomed. *European healthcare workers at risk!* Updated 2013 Sept. 29, 2013]; Available from: <http://www.eucomed.org/key-themes/patients-safety/elimination-of-sharps-injuries>.
61. Institute for Healthcare Improvement. *The IHI Triple Aim*. 2013 Sept 30, 2013]; Available from: <http://www.ihl.org/offerings/initiatives/tripleaim/pages/default.aspx>.
62. US Department of Health and Human Services. *2013 Annual Progress Report to Congress: National Strategy for Quality Improvement in Health Care*. 2013 Sept 30, 2013]; Available from: <http://www.ahrq.gov/workingforquality/nqs/nqs2013annlrpt.htm>.
63. Stone, P.W., et al., *CMS changes in reimbursement for HAIs: setting a research agenda*. *Med Care*, 2010. **48**(5): p. 433-9.
64. Services, C.f.M.a.M. *Frequently Asked Questions: Hospital Value-Based Purchasing Program*. 2012 March 9, 2012 January, 2014].
65. Services, C.f.M.a.M. *Bundled Payments for Care Improvement Initiative*. September 30, 2013 January, 2014]; Available from: <http://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-Sheets/2013-Fact-Sheets-Items/2013-01-31.html>.

66. Silver, M.J., et al., *Reduction of blood loss from diagnostic sampling in critically ill patients using a blood-conserving arterial line system*. Chest, 1993. **104**(6): p. 1711-5.
67. Silver, M.J., et al., *Evaluation of a new blood-conserving arterial line system for patients in intensive care units*. Crit Care Med, 1993. **21**(4): p. 507-11.
68. Woda, R.P., et al., *On the dynamic performance of the Abbott Safeset blood-conserving arterial line system*. J Clin Monit Comput, 1999. **15**(3-4): p. 215-21.

CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Any quotes used in this material are taken from independent third-party publications and are not intended to imply that such third party reviewed or endorsed any of the products of Edwards Lifesciences.

Edwards, Edwards Lifesciences, the stylized E logo, ccNexfin, FloTrac, Nexfin, PreSep, Swan-Ganz, TruWave, VAMP, VAMP Jr., and VAMP Plus are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2014 Edwards Lifesciences Corporation.
All rights reserved. AR11066 and AR11090